

SECRET
03 AUG

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <p style="text-align: center; font-size: 1.2em;">Steve Giuli</p>			
2. Address <input type="checkbox"/> Check if different than previously reported <p style="text-align: center; font-size: 1.2em;">1725 I Street NW Suite 300 Washington, DC 2000</p>			
3. Principal Place of Business (if different from line 2)			
City:	State/zip (or Country)		
4. Contact Name <p style="text-align: center; font-size: 1.2em;">Steve Giuli</p>	Telephone	E-mail (optional)	5. Senate ID #
7. Client Name <input checked="" type="checkbox"/> Self	6. House ID #		
Alpharma US Human Pharmaceuticals			

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-Decer)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES · Complete Either Line 12 OR Line 13	
<p style="text-align: center;">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p style="text-align: center;">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>51,000</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate exp accounting method. See instructions for description of opti</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Signature: Steven Giuli Date: 8/13/2003

Printed Name and Title STEVEN GIULI, Director of Legislative Affairs

LD-2 (REV. 4/03)

PAGE 1 of .

Registrant Name Steve Giuli Client Name Alpharma US Human Pharmc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page), LBR

16. Specific lobbying issues

See Attached sheets

17. House(s) of Congress and Federal agencies contacted Check if None

Senate
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steve Giuli</u>	<u>Legislative Director, Cong. Frank Pallone,</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Steven Giuli Date 8/13/2003

Printed Name and Title Steven Giuli, Director of Legislative Affairs

16: Specific Lobbying Issues

HCR

1. S. 54, Greater Access to Affordable Pharmaceuticals Act
2. S. 1225, Greater Access to Affordable Pharmaceuticals Act
3. S. 1, Prescription Drug and Medicare Improvement Act, Title VII, Access to Affordable Pharmaceuticals
4. HR 1, Medicare Prescription Drug and Modernization Act of 2003, Title XI, Access to Affordable Pharmaceuticals
5. Re: HR 2427, The Pharmaceutical Marketing and Access Act of 2003, Section 5, Use of Counterfeit-Resistant Technologies to Prevent Counterfeiting
6. FDA Generic Drug Rule, Docket No. 02N-0417

